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TOPICAL FORMULATIONS FOR THE 
TRANSDERMAL DELIVERY OF NIACIN 
AND METHODS OF TREATING 
HYPERLIPIDEMIA 
This application claims the bene?t of Provisional Appli 
cation Ser. No. 60/197,621 ?led Apr. 14, 2000. 
FIELD OF THE INVENTION 
This invention relates to topical formulations for trans 
dermal delivery of niacin and esters and alcoholic fatty-acid 
esters as described herein derivatives thereof and the trans 
dermal treatment of hyperlipidemia and hypercholester 
olemia With these agents. Therapeutic uses of the system are 
also described. The topical formulations are useful for, e.g., 
treating hyperlipidemia in a mammal. 
Hyperlipidemia and hypercholesterolemia are conditions 
that have a Well established correlation With increased risk 
of other conditions, such as heart attacks, atherosclerosis, 
and other deleterious ailments. There are numerous agents 
available for loWering cholesterol and lipid levels, including 
gem?briZol, probucol, and, more recently, the “statins” e.g, 
lovastatin. 
Niacin (nicotinic acid), a Water soluble B-complex 
vitamin, is used orally for the treatment of hyperlipidemia 
and has been shoWn to be effective in reducing total plasma 
cholesterol (C), loW density lipoproteins LDL-C and very 
loW density lipoprotein triglycerides (VLDL-triglycerides), 
all of Which are associated With health risks, While raising 
serum levels of high density lipoproteins (HDL-C) Which 
are considered a “healthy” lipoprotein, in patients With type 
II, III, IV, and V hyperlipoproteinemia. 
Although the mechanism by Which niacin alters lipid 
pro?les has not been Well de?ned, its mechanisms of action 
have been shoWn to include inhibition of free fatty acid 
release from adipose tissue (see Carlson, L. A., Froberg, S. 
O. and Nye, E. R., Nicotinic acid in the rat. 11. Acute effects 
of nicotinic acid on plasma, liver, heart, and muscle lipids, 
Acta Med Scand 180: 571—579, 1966), and increased lipo 
protein lipase activity (see Priego, J. G., Pina, M., Armijo, 
M., Sunkel, C. and Maroto, M. L., Action of eto?brate, 
clo?brate and nicotinic acid on the metabolism of lipids in 
normolipemic rats. Short term effects and method of action, 
Arch Farmacol Toxicol 5: 29—42, 1979). More than 14 
million Americans have elevated blood LDL-C levels. 
HMG-CoA reductase inhibitors (statins) are the most Widely 
used class of drugs for treating patients With elevated levels 
of LDL-C. Niacin, hoWever, is the only drug recommended 
by the American Heart Association for HDL improvement in 
primary prevention of cardiovascular diseases in addition to 
loWering LDL-C. Niacin therapy is not only very cost 
effective as a monotherapy but it also is bene?cial as a 
combination therapy because it complements the effects of 
other classes of lipid-loWering drugs. Niacin is a second or 
third choice for isolated, hypercholesterolemia because of a 
high incidence of side effects associated With oral niacin 
therapy. HoWever, it has a therapeutic advantage as a mono 
therapy When reduction of both LDL-C and triglycerides are 
desired such as for patients With severe combined hyper 
lipidemia. Niacin can also be used in combination With other 
cholesterol-loWering agents such as the “statins” to maxi 
miZe lipid-loWering activity. One study shoWs that a niacin/ 
lovastatin combination is highly effective in loWering LDL 
C, triglycerides and lipoprotein a[Lp(a)] While retaining 
niacin’s potency in raising HDL-C (Kashyap, M. L., Evans 
R., Simmons, P. D., Kohler, R. M. and McGoven, M. E., 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
NeW combination niacin/statin formulation shoWs pro 
nounced effects on major lipoproteins and Well tolerated, J 
Am Coll Card Suppl. A 35: 326, 2000). 
Niacin has been Widely used for reducing serum choles 
terol levels because it is considered a cost-effective therapy. 
In oral doses of 2 to 3 g daily, it reduces levels of total and 
LDL-C by an average of 20% to 30%, reduces triglyceride 
levels 35% to 55%, increases HDL-C 20% to 35%, and 
reduces Lp(a) in humans. Niacin also reduces total mortality 
as Well as mortality from coronary artery disease (see The 
Coronary Drug Project Research Group, JAMA 231: 
360—381, 1975; and Canner, P. L., Berge, K. G., Wenger, N. 
K., Stamler, J ., Friedman, L., Prineas, R. J. and FriedeWald, 
W., Fifteen year mortality in Coronary Drug Project patients: 
long-term bene?t With niacin, J Am Coll Cardiol 8: 
1245—1255, 1986.) and it helps to sloW or reverse the 
progression of atherosclerosis (see Blankenhorn, D. H., 
Nessim, S. A., Johnson, R. L., Samnarco, M. E., AZen, S. P. 
and Cashin-Hemphill, L., Bene?cial effects of combined 
colestipol-niacin therapy on coronary atheroscloerosis and 
coronary venous bypass grafts, JAIVIA 257: 3233—3240, 
1987.; and Cashin-Hemphill L.; Mack, W. J., Pogoda, J. M., 
Samnarco, M. E., AZen, S. P. and Blankenhorn, D. H., 
Bene?cial effects of colestipol-niacin on coronary athero 
sclerosis. A 4-year folloW-up, JAMA 264: 3013—3017, 
1990). 
Oral niacin therapy has side effects that limit its utility. 
Although niacin is a vitamin, it must be used in therapeutic 
doses to loWer cholesterol. At these doses, both immediate 
release and sustained-release niacin can have several side 
effects. The most common side effect of niacin is ?ushing, 
a Warm feeling in the skin usually associated With redness 
and sometimes itching. Flushing is not dangerous but most 
patients ?nd it very uncomfortable, Which seriously limits 
patient compliance With therapy. Niacin-induced ?ushing 
can be substantially attenuated by pretreatment With 
cyclooxygenase inhibitors, suggesting that the vasodilation 
is caused by a prostaglandin-mediated mechanism (see 
Carlson, L. A., Nicotinic acid and inhibition of fat mobiliZ 
ing lipolysis. Present status, of effects on lipid metabolism, 
Adv Exp Med Biol 109: 225—23 8, 1978). 
Liver function tests are alWays monitored in patients 
taking niacin since elevation of serum transaminase levels 
has been associated With niacin treatment, and sustained 
release niacin formulations have been associated With more 
serious liver problems (see McKenney, J. M., Proctor, J. D., 
Harris, S., and Chinchili, V. M., Acomparison of the ef?cacy 
and toxic effects of sustained- vs immediate-release niacin in 
hypercholesterolemic patients, JAMA 271: 672—777, 1994; 
and Stafford, R. S., Blumenthal, D. and Pasternak, R. C., 
Variations in cholesterol management practices of US. 
physicians, JAm Coll Cardiol 29: 139—146, 1997). Other 
possible side effects of oral niacin therapy include activation 
of peptic ulcers, gout, and Worsening of diabetes control. 
Given the potential for side effects, oral niacin therapy 
requires careful clinical monitoring. 
The pharmacokinetic pro?le of niacin taken orally is 
complex due to rapid and extensive ?rst-pass metabolism, 
resulting in a nonlinear relationship betWeen niacin dose, 
thus there is no correlation betWeen the lipid parameters and 
plasma niacin levels. For example, data shoW that Niaspan® 
doses of 1,000 mg results in an improvement in lipid pro?les 
With barely detectable increases in plasma niacin (see Phy 
sicians Desk Reference, 53rd edition, p 1505—1506, 1999). 
Niaspan® is an extended release niacin formulation 
approved by the FDA for the treatment of hypercholester 
olemia and hypertriglyceridemia (CapuZZi, D. M., Guyton, 
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J. R., Morgan, J. M., Goldberg, A. C., Kriesberg, R. A., 
Brusco, O. A. and Brody, J ., Ef?cacy and safety of an 
extended-release niacin (Niaspan): A long term study, Am J 
Cardiol 82: 74u—8 I u, 1998; and Morgan, J. M., CapuZZi, D. 
M., and Guyton, J. R., A neW extended-release niacin 
(Niaspan): Efficacy, tolerability, and safety in hypercholes 
terolemic patients,Am J Cardiol 82: 29u—34u, 1998). Thus, 
signi?cant improvement in the serum lipid pro?le can be 
achieved Without a dramatic increase in nicotinic acid 
plasma levels after the oral administration of niacin (see 
Knopp, R. H., Alagona, P., Davidson, M., Goldberg, A. C., 
Kafonek, S. D., Kashyap, M., Sprecher, D., Superko, H. R., 
Jenkins, S., Marcovina, S., Equivalent ef?cacy of a time 
release form of niacin (Niaspan) given once-a-night versus 
plain niacin in the management of hyperlipidemia, Metabo 
lism 47: 1097—104, 1998). This demonstrates that sustained 
elevation of blood levels of niacin is not required to achieve 
a therapeutic effect. Indeed, the data support the argument 
that tissue saturation With niacin appears to be the key factor 
in obtaining therapeutic bene?t. Prolonged loW-level expo 
sure via controlled release oral formulations is preferable to 
the high level, short exposures resulting from immediate 
release formulations because it avoids inconvenient dosing 
regimens and reduces unpleasant side effects. HoWever, 
controlled release oral formulations of niacin still shoW 
signi?cant degree of ?ushing and hepatic dysfunction. In 
vieW of the pharmacokinetic fate of oral niacin, the ideal 
method of niacin administration has yet to be achieved. 
Transdermal drug delivery is an attractive route due to the 
controlled input of these agents and avoidance of the hepatic 
?rst-pass effect. HoWever, it is unlikely that hydrophilic 
compounds such as niacin Will easily permeate across the 
skin. We demonstrate in the present study that the chemical 
modi?cation With fatty alcohols alloWs niacin to permeate 
the skin in a controlled manner for systemic delivery and to 
affect the blood lipid pro?le in animal models. Both chemi 
cal and enZymatic hydrolysis of prodrug esters of niacin 
have been extensively evaluated using human and rat plasma 
and hog liver carboxylesterase preparations described by 
Wernly-Chung, G. N., Mayer, J. M., Tsantili-Koulidou, A. 
and Testa, B., Structure-reactivity relationships in the chemi 
cal hydrolysis of prodrug esters of nicotinic acid, Int J 
Pharma 63: 129—134, 1990. The studies shoW that chemi 
cally stable niacin esters are excellent substrates of esterases. 
A study indicates that the binding of niacin esters mainly 
depends on lipophilicity (optimal log Pod/V523) and steric 
factors. Niacin esters up to hexyl nicotinate are commer 
cially available. 
Transdermal delivery systems are a convenient and effec 
tive alternative for the administration of many types of 
medications, including anti-anginals (nitroglycerin), hor 
mones (estrogens) and antihypertensives (cloncidine). 
Transdermal delivery is bene?cial because the agents are 
delivered directly into the blood stream, avoiding ?rst-pass 
metabolism in the liver, so that drug delivery is continuous 
and sustained. Transdermal delivery also provides a sus 
tained and consistent delivery of medication, avoiding peaks 
and valleys in blood levels Which are often associated With 
oral dosage forms and Which are usually undesirable. Thus, 
using transdermal delivery, one can administer loWer doses 
of drug to achieve the same therapeutic effect compared to 
oral administration, reducing or eliminating dose-dependent 
side effects. 
Preparing suitable formulations of medications is a chal 
lenging task, and many hurdles must be overcome to achieve 
a suitable topical dosage form. The skin, Which has protec 
tive layers designed to prevent penetration of foreign matter, 
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must be suf?ciently penetrated to provide the active agent to 
the desired site for absorption into the bloodstream. Skin is 
a complex organ system, consisting of multiple layers. The 
uppermost, or “stratum corneum” layer of skin consists of 
non-living material derived primarily from the terminal 
differentiation of epidermal keratinocytes, and provides a 
protective barrier for the underlying components of skin. 
The epidermis contains a number of cell types, although 
keratinocytes are the major cell type. Dermal ?broblasts are 
embedded Within a matrix comprised of collagen, elastin, 
proteoglycans, and other extracellular matrix molecules. 
Blood capillaries are found in the dermis, but the epidermis 
is non-vascular. 
Additionally, the drug itself must be suitable for admin 
istration. The siZe of a drug molecule, its charge, and 
polarity are factors that contribute to the ability of the agent 
to penetrate the skin to the desired site or to blood vessels for 
systemic distribution. 
The bene?ts of transdermal delivery indicate that trans 
dermal delivery systems of niacin for, e.g, the treatment of 
hyperlipidemia or vitamin therapy are desirable. 
It is an object of the present invention to provide trans 
dermal delivery formulations and systems for the systemic 
delivery of niacin to a patient, e.g., a mammal such as a 
human, Wherein the niacin is provided in a pro-drug of 
niacin, e.g., nicotinic acid esters and fatty acid esters of the 
corresponding alcohol. These are referred to herein as “pro 
niacin”. 
It is also an object of the invention to treat hyperlipidemia 
and hpercholesterolemia via transdermal delivery of niacin 
using pro-niacin esters. 
These and other objects of the invention are achieved by 
the present invention Which is described in the folloWing 
disclosure. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is depicts the NAD content in mouse skin treated 
With myristyl nicotinate for 7 days vs. untreated skin; 
FIG. 2 is a table shoWing lipid response to Niaspan®; 
FIG. 3 is a table of the mean steady-state pharmacokinetic 
parameters for plasma niacin; 
FIGS. 4a and 4b are graphs comprising NAD content in 
mouse skin treated With myristal niacin for 7 days (4a) vs. 
untreated skin (4b); 
FIG. 5 is a graph shoWing the cholesterol loWering effects 
of transdermal lauryl niacin ester vs. oral niacin in hairless 
mice against a control; and 
FIGS. 6a—a' is a graph shoWing the effect of oral niacin 
and transdermal lauryl niacin on the lipid pro?les of apoB/ 
CETP transgenic mice. 
FIG. 7 is a graph shoWing the effect of nicotinoyl laurate 
compared to the results shoWn in FIG. 6. 
FIG. 8 shoW the general chemical structures of nicotinate 
and nicotinyl compounds suitable for use With the present 
invention. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Transdermal delivery is an attractive alternative route of 
niacin administration that circumvents toxic ?rst-pass 
hepatic actions. The topical delivery system of invention 
takes into account the partitioning of niacin through the 
stratum corneum Which is at least partly controlled by the 
esteri?cation of niacin or addition of a fatty acid to form a 
US 6,677,361 B2 
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nicotinyl compound, collectively the pro-niacins of the 
present invention, such as those soWn in FIG. 7. The rate and 
site of metabolic conversion of the pro-niacin contribute to 
penetration of the skin and to systemic absorption into the 
blood vessels in the loWer skin layers. The primary consid 
eration for transdermal delivery of many hydrophilic drugs 
such as niacin is the high diffusional resistance of the intact 
stratum corneum. Molecular modi?cation of niacin the drug, 
more commonly in the form of a prodrug, circumvents this 
problem. 
Niacin pro-drugs, e.g., nicotinic acid esters are preferred 
over nicotinic acid because they provide prodrugs With 
highly desirable formulation properties for transdermal 
delivery. Additionally, conversion to niacin by esterases 
present in skin provides sustained release of the active 
ingredient. The C10—C18 esters of niacin are particularly 
preferred, although suitable formulations can be prepared 
With C1 to C22 nicotinic acid esters. The niacin esters and 
nicotinyl compounds may be straight chain or branched, 
substituted or unsubstituted provided the total number of 
carbons meets the criteria set forth herein. 
It is preferred that the compositions comprise from 1 to 
30% by Weight of the niacin prodrug, preferably 1—20%, and 
most preferred 1—10%. 
The niacin or niacin prodrug preferably has a log P of 
from 0.5 to about 12, 4.5 to 10, most preferably from 4.8 to 
9.7 When measured using Water/octanol partitioning. 
To evaluate the ef?cacy of transdermal delivery, a hairless 
mouse model and an apoB/CETP double transgenic mouse 
model Was used. The apoB/CETP model provides a suitable 
model of human lipid metabolism as these mice are knoWn 
to display a lipoprotein cholesterol distribution most similar 
to that of normolipidemic humans. Transgenic mice express 
ing speci?c human genes have been Widely used to inves 
tigate the lipid metabolism and to test potential hypolipi 
demic drugs, providing the potential for better prediction of 
the human response. Transgenic mice expressing both 
human apoB100 and human CETP shoW a human-like 
serum HDL-C/LDL-C distribution and are commercially 
available. ApoB100 is a protein component of VLDL and 
LDL, and it is the ligand responsible for binding to the LDL 
receptor, Whereas CETP mediates the distribution of lipids 
among different classes of lipoproteins. The lipoprotein 
cholesterol pro?le of the double transgenic mice is signi? 
cantly different from that of nontransgenic, human apoB 
single transgenic and CETP single transgenic mice, in Which 
most of the cholesterol is found in the HDL fractions. The 
apoB100/CETP double transgenic mice display the lipopro 
tein cholesterol distribution most similar to that of normo 
lipidemic humans (i.e., a ratio of LDL-C to HDL-C of 
approximately 2 to 1) When fed a normal choW diet 
described by Grass, D. S., Sainai, U., Felkner, R. H., 
Wallace, R. E., Lago, W. J. P., Young, S. G. and SWanson, 
M. E., Transgenic mice expressing both human apolipopro 
tein B and human CETP have a lipoprotein cholesterol 
distribution similar to that of normolipidemic humans, J 
Lipid Res 36: 1082—1091, 1995. 
The topical formulations of the present invention can be 
used to loWer cholesterol and/or lipids in a patient in need 
thereof, mammals and humans, by applying a suf?cient 
amount of a transdermal formulation containing a suf?cient, 
i.e. therapeutically effective amount of niacin pro-drug in a 
suitable topical base to the skin of a subject to reduce serum 
cholesterol and/or lipid levels of LDL, VLDL’s, or to 
increase serum HDL levels. Thus, the formulations may be 
used to prevent hyperlipidemia and hypercholesterolemia, or 
to treat those conditions. 
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EXAMPLES 1 AND 2—PREPARATION OF 
NIACIN ESTERS 
Example 1 
Nicotinic acid esters Were prepared by treating nicotinyl 
chloride With triethylamine (TEA), dimethylaminopyridine 
(DMAP) and various C1 to C18 alcohols under nitrogen (all 
chemicals obtained from Sigma Aldrich). The resultant 
esters Were separated by silica gel column chromatography 
and converted to their respective HCl salts for further 
puri?cation. Thin layer chromatography (TLC) and I H-NMR 
con?rmed the purity and identity of the ?nal products listed 
in Table 1 beloW. Examinations by TLC Were performed on 
Analtech Uniplate silica gel GF plates. Column chromato 
graphic puri?cations Were done With silica gel (Merck, 60 A, 
230—400 mesh for ?ash chromatography). 
Example 2 
Female hairless mice (HRS-J. 6—8 Weeks old Were used.) 
These Were housed in solid bottom cages provided With 
sterile feed and Water and lithium, With a 14:10 light-dark 
cycle. The nicotinic acid esters of Example 1 Were applied 
With a gloved ?nger daily to the backs of hairless mice in 
200 mg of Vanicream LiteTM skin care lotion 
(Pharmaceutical Specialties, Inc., containing puri?ed Water, 
White petrolatum, ceteareth alcohol and ceteareth-20, pro 
pylene glycol, sorbitol solution, simethicone, glyceryl 
monostearate, polyethylene glycol monostearate, sorbic acid 
and BHT) at concentrations in the range of 0.5 to 2.0% 
(Wt/Wt) for one Week. Control mice received 200 mg of the 
lotion alone. The animals Were euthaniZed by cardiac injec 
tion of pentobarbital prior to skin excisions. Dorsal and 
ventral skin samples Were immediately froZen in liquid 
nitrogen and stored at —80° C. 
Since niacin is converted to NAD in tissue, NAD content 
Was used as a marker of niacin saturation (Fu, C. S., 
SWenseid, M. E., Jacob, R. A. and McKee, R. W., Biochemi 
cal markers for assessment of niacin status in young men: 
levels of erythrocyte niacin coenZymes and plasma 
tryptophan, J Nutrition 119: 1949—195 5, 1989). The sys 
temic transdermal delivery of niacin Was assessed by deter 
mining the NAD content of a skin site that is remotely 
located from the site of topical application. Demonstration 
of tissue saturation of niacin using a transdermal delivery 
system according to the invention is shoWn in FIG. 1, Which 
shoWs treatment With myristyl nicotinate. 
For NAD and protein analyses, the tissue Was homog 
eniZed using a Polytron in 1 ml of ice-cold 0.5 M HClO4 and 
centrifuged at 3,000 rpm for 15 min. The supernatant Was 
neutraliZed With ice-cold 2 M KOH/0.66 M KHZPO4 for the 
NAD assay. The pellet Was dissolved in 1 ml of 0.1 M NaOH 
for protein assay. NAD content Was assessed based on the 
principle of enZymic cycling (Jacobson, E. L. and Jacobson, 
M. K., Tissue NAD as biochemical measure of niacin status 
in humans, Methods Enzymol 280: 221—230, 1997). The 
BCA method (Pierce Chemical Co.) Was employed for 
protein determination. Determination of Poet/W Was con 
ducted using the reversed-phase HPLC method as reported 
by Harnisch M., Mokel H., Relationship betWeen Log PoW 
shake-?ask values and capacity factors derived from 
revesed-phase high-performance liquid chromatography for 
n-alkyl benZenes and some OECD reference substances. J. 
Chrom, 282, (315—332), 1983. Results are shoWn in Table 1. 
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TABLE 1 
Properties of Niacin Prodrugs 
Erythematous 
Alkyl Carbon Chain Length Log P Value" Response 
1 carbon 0.84 Yes 
2 carbons 1.3 Yes 
4 carbons 2.4 Yes 
6 carbons 3.5 Yes 
8 carbons 4.8 Yes 
10 carbons 5.8 Slight 
12 carbons 6.6 No 
13 carbons 7.5 No 
14 carbons 7.6 No 
15 carbons 8.3 No 
16 carbons 9.2 No 
18 carbons 9.7 No 
*Determined as described in Harnisch and Mokel, supra. 
The results summarized in Table 1 supra show that 
nicotinic acid esters with log P values between about 6.0 and 
about 8.0 are the preferred compounds for transdermal 
delivery of niacin to achieve tissue saturation, since esters 
with log P values of less than about 6, including C1 to C8 
esters, cause erythematous response, while esters with log P 
values greater than 6 do not. The C10 ester showed reduced 
erythematous response compared to C8 or lower esters. 
Example 3 
Esters of niacin were also synthesized according to known 
methods described by Ono, N., Yamada, T. Saito, T. Tanaka, 
K. and Kaj i, A., A convenient procedure for esteri?cation of 
carboxylic acids, Bull. Chem. Soc. Jpn. 51:2401—2404, 
1978. The treatment of niacin with various alkyl bromide 
and 1,8-diazbicyclo[5,4,0]undec-7-ene (DBU) in benzene 
under nitrogen resulted in esters that could be separated by 
silica gel column chromatography. The purity and identity of 
the ?nal products were con?rmed by TLC, 1H-NMR 
spectroscopy, reversed-phase HPLC, and elemental analy 
sis. Niacin, DBU and all the alkyl bromides were purchased 
from Sigma-Aldrich. Examinations by TLC were performed 
on Analtech Uniplate silica gel GF plates. Column chro 
matographic puri?cations were done with silica gel (Merck, 
60 A, 230—400 mesh for ?ash chromatography). 1H-NMR 
spectra were recorded on a Varian Gemini-300 NMR spec 
trometer using tetramethylsilane as the internal reference. 
Example 4 
Lauryl niacin esters prepared according to Example 3 was 
evaluated in hairless mice using the procedure set forth in 
Example 2 except that concentrations of 1 to 10% wt/wt. 
lauryl niacin ester were used. NAD and protein determina 
tion were conducted as described in Example 2, and the 
results are shown in FIGS. 4a and 4b. 
Additionally, a plasma lipid analysis was performed by 
taking fasting (16 h) blood samples of the hairless mice were 
obtained at the beginning, at 30 days and 60 days from the 
retroorbital plexus, and at the end of treatment by cardiac 
puncture. The animals were euthanized by cardiac injection 
of pentobarbital prior to blood collection. Blood was col 
lected into microfuge tubes containing 10 pl of heparin, 
plasma separated by centrifugation at 2,000><g for 15 min 
utes and stored at —80° C. until analysis within 1 week. Total 
cholesterol, HDL-C and triglycerides were measured 
enzymatically, using a clinical chemistry analyzer Syncrhon 
CX7 by Beckman). Results are shown in FIGS. 4a and 4b. 
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Example 5 
Female apoB/CETP double transgenic mice (Taconic 
Biotechnology, Germantown, NY.) were divided into 6 
groups and housed in groups of 6 animals per. The lauryl 
ester was used as a 5% lotion formulation and applied to the 
shaved backs of the test animals receiving a standard diet, 5 
times a week for 4 weeks. For oral administration, niacin 
(sodium salt) was dissolved in drinking water at a concen 
tration of 0.75% (0.63% as free acid). Niacin intake was 
estimated from the water consumed. The estimated daily 
niacin intake was approximately 1,400 mg/kg. 
The oral dose used was 760 mg/kg/day and the topical 
dose was 250 mg/kg/day as niacin. The oral niacin dose 
chosen is in the range of 500 to 900 mg/kg/day typically 
used in preclinical rodent studies described by Santos, K. F. 
R., Oliveira, T. T., Nagem, T. J., Pinto,A. S. and Oliveira, M. 
G. A., Hypolipidaemic effects of naringenin, rutin, nicotinic 
acid and their associations, Pharmacol Res 40, 493—496, 
1999. The oral dose, on the basis of body surface area, is 
equivalent to a human dose of 3.7 g/day, while the topical 
dose is equivalent to 1.2 g/day. 
For topical administration, niacin lauryl esters was 
applied daily to the shaved backs of mice in 200 mg of lotion 
at concentrations of 1, 2, 5 and 10% (wt/wt) for 13 weeks. 
Per 25-g mouse, the daily topical doses would be in the 
range of 34 to 340 mg/kg as niacin. Control mice received 
equal amounts of the vehicle lotion alone. A lipid analysis 
was performed as described in Example 4. Results are 
shown in FIGS. 6a—a'. 
Improvement of lipid pro?les of apoB100/CETP trans 
genic mice treated with niacin prodrug. The effect of trans 
dermal delivery of lauryl niacin ester on plasma lipid 
pro?les in a comparison with oral niacin in the apoB100/ 
CETP double transgenic mice for 90 days. A total of six 
groups of six animals were used in this study. For topical 
administration, lauryl niacin ester was applied daily to the 
shaved backs of mice. For oral administration, niacin 
(sodium salt) was dissolved in the drinking water. After 90 
days, the topical treatment at one-fourth the dose of the oral 
treatment lowered total cholesterol, triglycerides, and the 
LDL-C fraction by 15, 33 and 38% while HDL-C was 
elevated by 8%. The oral treatment lowered total 
cholesterol, triglycerides, LDL, and HDL-C fractions by 29, 
37, 45% and 13%, respectively. These results show that 
lauryl nicotinate can be highly effective as a transdermal 
therapeutic for positively modulating serum lipid pro?les. 
The results show that the topical treatment lowered total 
plasma cholesterol level by 52%, whereas oral niacin low 
ered total cholesterol by 12%. 
The results show niacin pro-drugs, e.g., niacin esters, can 
be applied dermally as a prodrug to control blood lipid 
imbalance as an alternative to oral niacin that circumvents 
?ushing and potentially toxic ?rst-pass hepatic effects. The 
results show that the topical treatment lowered total plasma 
cholesterol level by 52%, whereas oral niacin lowered total 
cholesterol by 12%. 
The myristyl- and lauryl esters of niacin show no cuta 
neous vasodilation, indicating that niacin prodrugs can be 
made without such an undesirable effect. They provide 
prodrugs with highly desirable formulation properties for 
transdermal delivery and conversion to niacin by esterases 
present in skin will provide a sustained release of the active 
ingredient without vasodilation for optimum systemic deliv 
ery. The results in animal models strongly suggest that the 
transdermal approach can be successfully applied to the 
overall improvement of lipid pro?les by niacin 
administration, in humans or other mammals. 
US 6,677,361 B2 
Niacin and nicotinic acid esters and nicotinyl compounds 
of the present invention penetrate and saturate tissue When 
administered to a subject, and as discussed above, tissue 
saturation is related to reduction in serum cholesterol and 
lipid levels shoWing transdermal delivery of niacin, particu 
larly in ester form, Will effectively reduce serum LDL and 
VLDL levels and/or increase serum HDL levels. 
The nicotinic acid esters are suitable for transdermal 
delivery, particularly C10 or greater esters, e.g., C10—C18 
and most preferably C12—C16. HoWever, suitable formula 
tions can be prepared With C8 or loWer esters, and they are 
included Within the scope of the invention. Corresponding 
nicotinyl compounds are also effective. 
In addition to creams and lotions, topical formulations 
such as shampoos, liquids such as eye Washes, balms and 
sticks such as lip balms and deodorant sticks, soaps, patches, 
bandages, suturing threads, coated implant devices, and any 
other type of system designed for topical application. Suit 
able pharmaceutical vehicles Will be used to prepare the 
transdermal formulations of the invention, including 
petrolatum, Whitepsol ointment, various lotions, emulsion 
bases, creams, and the like. 
Most preferred is a transdermal delivery system. Suitable 
transdermal delivery systems (patches) for delivery of nico 
tine are knoWn in the art, such as those described in US. Pat. 
No. 4,839,174; 4,943,435; and 5,016,652. Many other 
eXamples of these types of devices are knoWn in the art. 
Typical transdermal systems include a reservoir or matrix 
containing the drug, and an adhesive layer Which is perme 
able to the active agent, in this case niacin and more 
preferably nicotinic acid esters. An adhesive layer, Which 
may be the same as the permeable layer, adheres to the skin 
of a subject, alloWing the agent to be released and absorbed 
into the skin for subsequent systemic circulation and distri 
bution to other tissue. In operation, the device Will trans 
dermally deliver a suf?cient dose of niacin or nicotinic acid 
ester to deliver a suf?cient amount of niacin to saturate the 
tissue of the subject With niacin, and to provide a reduction 
in total cholesterol, VLDL, or LDL levels and/or an increase 
or improvement in HDL levels. Improvements in total 
cholesterol are conveniently expressed as a loWering of the 
ratio of total cholesterolzHDL or LDLzHDL. The result shoW 
that transdermal delivery of the compounds described herein 
produce improvements in the cholesterol and lipid pro?les 
of the subjects similar to those knoWn to be produces With 
oral niacin therapy. 
Other features of the invention Will be clear to the skilled 
artisan and need not be set forth herein. 
All references cited herein are incorporated by reference 
in their entireties. 
We claim: 
1. A method of loWering serum triglyceride in a subject in 
need thereof comprising topically administering to said 
subject an amount of a compound of formula 
O O 
R i (l 3 0/ (l 3 O R 
e 2 or 6 2| 
\1 \1 
N N 
Wherein, in each compound R is C1—C22 alkyl, in an 
amount suf?cient to reduce serum triglyceride in said 
subject. 
2. The method of claim 1, Wherein R is C10—C18 alkyl. 
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3. The method of claim 1, Wherein said compound is 
Wherein R, is C1—C22 alkyl. 
4. The method of claim 1, Wherein said compound is 
Wherein R is C1—C22 alkyl. 
5. The method of claim 1, Wherein said compound is 
myristyl nicotinate. 
6. The method of claim 1, Wherein said compound is a 
lauryl niacin ester. 
7. A method for loWering serum LDL in a subject in need 
thereof comprising topically administering to said subject an 
amount of a compound of formula 
O O 
/R i (l 3 O (l 3 O R 
e 2 or 6 2| 
\1 \1 
N N 
Wherein in each compound R is C1—C22 alkyl, in an 
amount suf?cient to reduce serum LDL in said subject. 
8. The method of claim 7, Wherein R is C10—C18 alkyl. 
9. The method of claim 7, Wherein said compound is 
Wherein R is C1—C22 alkyl. 
10. The method of claim 7, Wherein said compound is 
Wherein R is C1—C22 alkyl. 
11. The method of claim 7, Wherein said compound is 
myristyl nicotinate. 
12. The method of claim 7, Wherein said compound is a 
lauryl niacin ester. 
13. A method of increasing serum HDL levels in a subject 
in need thereof comprising topically administering to said 
subject an amount of a compound of formula 
US 6,677,361 B2 
11 12 
O O O O 
R 1 R 1 (l 3 0/ (l 3 O R 5 (l 3 0/ (l 3 O R 
e 2 Or 6 2| 6 2 or 6 2| 
\1 \1 \1 \1 
N N N N 
wherein in each compound R is C1—C22 alkyl, in an wherein in each Compound R is C1—C22 alkyl, in an 
amount sllf?cient I0 raise Serum HDL in said subject 10 amount suf?cient to lower the ratio of total choles 
14. The method of claim 13, Wherein R is C10—C18 alkyl. tergli PLDL, aIId/OI (ii) lOWer the ratio of LDL;HDL in 
15. Th th d f l ' 13 h ' 'd d ' Sal S11 JeCL 
6 me O O C alm , W erem Sal Compoun 1S 18. The method of claim 17, Wherein R is C10—C18 alkyl. 
15 19. The method of claim 17, Wherein said compound is 
20 
Wherein R is C1—C22 alkyl. 
16. The method of claim 13, Wherein said compound is wherein R is C1_C22 alkyL 
O 25 20. The method of claim 17, Wherein said compound is 
| O R i 
6\1 2 (l 3 O R 
N 30 6 2l 
\1 
N 
Wherein R is C1—C22 alkyl. 
17. A method of improving total cholesterol pro?le in a wherein R is C1_C22 alkyL 
subject in need thereof comprising topically administering to 35 
said subject an amount of a compound of formula * * * * * 
